Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Medios AG    ILM1   DE000A1MMCC8

MEDIOS AG

(ILM1)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medios : Quarterly Statement as of 30 September 2020

11/12/2020 | 06:25am EST

QUARTERLY STATEMENT AS OF 30 SEPTEMBER 2020

Medios AG: Further dynamic growth

  • Revenue growth of around 22% in the first nine months of 2020
  • Corona-relatedspecial effects continue to burden earnings - but third quarter earnings improve compared to second quarter of 2020
  • Forecast for the full year confirmed

Medios AG ("Medios"), one of the leading Specialty Pharma companies in Germany, has continued its dynamic revenue growth in the first nine months of 2020 (9M 2020). Consolidated revenue from January to September increased by around 22% to €453m compared to the same period of the previous year (€372m). Consolidated earnings before interest, taxes, depreciation and amortization, adjusted for extraordinary expenses (EBITDA before extraordinary items), amounted to €10.2m (previous year's period: €14.1m). Consolidated earnings before taxes, adjusted for extraordinary items (EBT before extraordinary items), amounted to €8.0m (previous year's period: €12.8m). The disproportionate earnings performance in relation to revenue is due in particular to the corona-related special effects: The stockpiling that began in the first quarter as a result of the allocation of quotas for certain drugs was carried out at higher purchase prices and thus led to lower margins than planned. This effect continued in the second and third quarter. But compared to the weak second quarter, Medios shows a positive development for the third quarter 2020: Revenue rose by 23% to around €160m, and EBT before extraordinary items have significantly improved to €3.1m compared to the second quarter. Medios confirms the forecast for the 2020 financial year.

Significant events and developments in the reporting period

  • Acquisition of Kölsche Blister GmbH
    With the acquisition of Kölsche Blister GmbH in the first quarter of 2020, Medios' business model was expanded with the service of patient-specific blistering. This is the patient- related repackaging of finished pharmaceuticals on individual request.
  • Re-placementoversubscribed several times - free float over 60%
    In mid-May 2020, 600,000 shares of Medios AG were placed. The shares were sold to international institutional investors as part of a private placement. After a short time, the offer was oversubscribed more than three times. The shareholders were not diluted.

1

  • Initiation of coverage by Jefferies
    In May 2020, Jefferies Group LLC, the largest independent global full-service investment banking company headquartered in the USA, initiated the coverage of Medios AG and has been reporting on the Company's development since then.
  • Financing measures
    In the first quarter, Medios has signed a syndicated loan agreement in the amount of €62.5m. As part of a cash capital increase successfully carried out at the beginning of June
    2020, Medios generated gross issue proceeds of around €53m excluding shareholders' subscription rights, which led to an increase in share capital of almost 10.0% to around €16.1m.
    The funds generated through the aforementioned capital-raising activities are intended to be used to finance the organic and inorganic growth and to make further acquisitions when required in order to benefit from the consolidation of the pharmaceutical market.
  • Centralization of administration and rental of an additional building
    In April, the administrative units were consolidated at new premises in Berlin-Mitte. In addition, Medios signed a contract in July to rent another building with a total area of around 4,500m2 at an existing location in Berlin. In particular, the Company intends to establish additional laboratories for the production of patient-specific therapies and to optimize logistics. In addition, the majority of the operating activities in Berlin are to be concentrated at this new Medios location.
  • Further development of mediosconnect
    Medios has further advanced the development and services of the digital platform mediosconnect. This self-developed platform connects doctors, health insurance companies and specialized partner pharmacies with each other and serves as an ordering and billing portal. mediosconnect simplifies the ordering and billing processes and thus contributes to an increase in efficiency in the health system.
    The number of users as well as the number of ordering and billing processes carried out is constantly increasing. This is partly due to the introduction of the software in another federal state (Mecklenburg-Vorpommern) in addition to Berlin.
    In a next step, Medios intends to establish an e-prescription-capable platform that offers added value for doctors, health insurance companies, specialized partner pharmacies and patients, so that both these stakeholders and Medios itself, can benefit from the increasing digitalization in the healthcare system.
  • Successful implementation of the new indication hemophilia
    Due to the new legal regulation for the drug supply of hemophilia patients, effective from 1 September 2020, Medios was able to successfully start distribution in the previously inaccessible indication area. Such therapies must be administered to patients throughout their lives and are among the most expensive therapies worldwide.

2

  • Inclusion in the SDAX
    On 21 September 2020, Medios AG was included in the selection index of Deutsche Börse SDAX. The SDAX comprises the 70 largest companies below the MDAX in terms of market capitalization and trading volume.
  • Growing number of employees
    As of 30 September 2020, the Medios Group had a total of 276 employees, 94 more than in the previous year (30 September 2019: 182 employees).

Significant events after the end of the reporting period

  • Changes in the Executive Board with effect from 1 January 2021
    In October, the Supervisory Board of Medios AG decided to appoint Matthias Gärtner, CFO, additionally as Chairman of the Executive Board with effect from 1 January 2021. Furthermore, his Executive Board contract is shortly to be extended prematurely by two years to 30 June 2023. The acting Chairman of the Executive Board, Manfred Schneider, will not extend his contract, which is planned to expire on 31 December 2020, but will leave the Executive Board due to family reasons. Therefore, the Executive Board will consist of a three-member team with the other current members Mi-Young Miehler (COO) and Christoph Prußeit (CINO).
    As founder and major shareholder, Manfred Schneider will remain closely associated with Medios AG and is to become a key member of a new Advisory Board to be established for the Company. In addition, Manfred Schneider has already agreed to a voluntary six-monthlock-up agreement for the major part of his Medios shares.
  • Research coverage extended
    Metzler Capital Markets initiated the coverage of Medios AG at the end of October and recommended the shares of the Company for purchase ("Buy"). In addition to Metzler Capital Markets, Medios continues to be covered by Berenberg, Jefferies, Kepler Cheuvreux and Warburg.

Financial performance and financial position

Unless otherwise stated, the following statements refer to the first nine months of the current 2020 financial year. In the first nine months of 2020, revenue of the Medios Group increased by 21.9% to around €453m compared to the same period last year (€372m). The largest growth driver was the Pharmaceutical Supply segment with a plus of €72.1m or 21.6% to €406.0m (previous year's period: €333.9m). The Patient-specific Therapies segment increased its revenue by €9m or 23.8% to €46.5m (previous year's period: €37.6m). Of this growth, €3.5m are attributable to the inclusion of Kölsche Blister GmbH revenue from the second quarter of 2020 onwards. Revenue in the Services segment increased by €0.1m or 103.9% to €0.3m (previous year's period: €0.2m). The segment generates external revenues with IT services for partner pharmacies.

3

All revenues were generated almost exclusively within the Federal Republic of Germany. In line with revenue growth, the number of specialized pharmacies supplied increased significantly to around 330. The Company was thus able to notably expand its partner network in the first nine months of the year (31 December 2019: 200 partner pharmacies). Through the acquisition of Kölsche Blister GmbH in the first quarter of 2020, around 80 partner pharmacies were integrated into the network.

In the first nine months of 2020, EBITDA before extraordinary items decreased by €3.9m or 27.3% to €10.2m compared to the same period last year (€14.1m). EBT before extraordinary items fell by €4.8m or 37.5% to €8.0m (previous year's period: €12.8m).

Due to the above-mentionedcorona-related special effects, which led to higher purchase prices and thus to lower margins, EBITDA before special effects in the Pharmaceutical Supply segment decreased as a result from €8.5m in the first nine months of 2019 to €6.0m in the first nine months of 2020. EBITDA before special effects in the Patient-specific Therapies segment decreased slightly to €4.3m compared to €4.6m in the previous year, which is mainly due to higher internal billing. The Services segment achieved an EBITDA before special effects of €-0.1m, compared to €0.9m in the same period of the previous year. The previous year included one-off proceeds of €0.9m from the sale of the property in Berlin-Charlottenburg.

EBITDA and EBT were adjusted for extraordinary items due to stock options in the amount of €0.6m, expenses for M&A activities of €0.6m (EBITDA) and €0.9m (EBT), respectively, and the amortization of the customer base capitalized in 2018 following the acquisition of operating units of BerlinApotheke Schneider & Oleski oHG, as well as the addition of new customers through the acquistition of Kölsche Blister GmbH in the amount of €0.5 million.

The operating cash flow increased by €2.9m to €6.9m.

Total assets amounted to €208.9m as of 30 September 2020 (previous year: €116.6m). The increase is mainly driven by increased inventories for stockpiling as a result of the COVID-19 pandemic and the entry into the hemophilia product area, while trade payables increased in the opposite direction. The successful cash capital increase led to an increase in cash and cash equivalents as well as in equity, which amounted to €140.0m as of 30 September 2020. The equity ratio nevertheless fell to 67.0%.

Despite the continuing temporary corona-related effects, the third quarter of 2020 shows a significant improvement in both revenues and earnings compared to the second quarter of 2020: Revenue increased from €130m (Q2/2020) to €160m (Q3/2020). EBT before extraordinary items rose to €3.1m (Q3/2020) compared to the second quarter of 2020, when it was €1.2m.

4

Outlook

Despite the challenging market environment, Medios continues to expect dynamic revenue growth. The Company assumes that the extraordinary corona-related special effects in connection with the quota allocation will continue in the fourth quarter of 2020 and will burden the Company's earnings.

According to the forecast revised on 5 August 2020, Medios expects consolidated revenue for the 2020 financial year - including the acquisition of Kölsche Blister GmbH in March 2020 - to amount to approximately €610 to 630m. In addition, Medios expects an EBITDA before extraordinary items of around €14.0 to 15.0m and an EBT before extraordinary items of around €11.5 to 12.5m. Furthermore, the Company remains optimistic that it will be able to reach the one billion € mark in revenues by 2023 at the latest.

5

Key financials (IFRS)

In € thousand

Revenue

  • Pharmaceutical Supply
  • Patient-specificTherapies
  • Services

Earnings before interest, taxes, depreciation and amortization (EBITDA)

Margin (in % of Revenue)

EBITDA without extraordinary expenses*

Margin (in % of Revenue)

  • Pharmaceutical Supply
  • Patient-specificTherapies
  • Services

Consolidated earnings before taxes (EBT)

Margin (in % of Revenue)

EBT without extraordinary expenses*

Margin (in % of Revenue)

  • Pharmaceutical Supply
  • Patient-specificTherapies
  • Services

Comprehensive income after taxes

Earnings per share (in €)

Undiluted

Diluted

Investments (CAPEX)

Cash flow from operating activities

  • Extraordinary expenses
    • Expenses from share option programs
    • Amortization of the customer base
    • Other expenses M&A
    • Financial expenses M&A

Balance sheet total

Equity

Equity ratio (in %)

9M 2020

9M 2019

Delta in %

Q3 2020

Q3 2019

Delta in %

452,900

371,679

21.9

160,015

143,172

11.8

406,044

333,938

21.6

143,970

129,661

11.0

46,544

37,588

23.8

15,940

13,429

18.7

312

153

103.9

106

83

27.7

9,057

13,089

-30.8

2,972

6,019

-50.6

2.0%

3.5%

1.9%

4.2%

10,235

14,087

-27.3

3,760

6,375

-41.0

2.3%

3.8%

2.4%

4.5%

5,958

8,543

-30.3

1,829

3,181

-42.5

4,340

4,620

-6.1

1,412

1,817

-22.3

-63

924

-106.9

519

1,368

-62.1

5,976

11,358

-47.4

1,802

5,457

-67.0

1.3%

3.1%

1.1%

3.8%

8,013

12,811

-37.5

3,122

5,965

-47.7

1.8%

3.4%

2.0%

4.2%

4,951

8,121

-39.0

1,476

3,038

-51.4

3,528

4,020

-12.2

1,129

1,693

-33.3

-466

670

-169.6

516

1,224

-57.9

4,269

7,958

0.0

1,101

3,987

-72.4

0.28

0.55

-49.1

0.07

0.27

-74.1

0.27

0.54

-50.0

0.07

0.27

-74.1

3,140

2,307

36.1

925

1,278

-27.6

6,947

4,018

72.9

28

2,935

-99.1

584

998

-41.4

195

356

-45.3

503

456

10.3

175

152

15.5

594

0

n/a

594

0

n/a

356

0

n/a

356

0

n/a

30/09/2020

31/12/2019

Delta in %

208,945

116,567

79.2

139,972

81,627

71.5

67.0%

70.0%

6

IFRS-group financial interim statement as at 30 September 2020

Statement of comprehensive income

In € thousand

Revenue

Change in stocks of finished goods and work-in-progress

Work performed and capitalized

Other income

Cost of materials

Personnel expenses

Other expenses

Earnings before interest, taxes, depreciation and amortization (EBITDA)

Depreciation and amortization

Earnings before interest and taxes (EBIT)

Financial expenses

Financial income

Consolidated earnings before taxes (EBT)

Taxes

Consolidated earnings after taxes

Total consolidated earnings

Undiluted earnings per share (in €)

Diluted earnings per share (in €)

9M 2020

9M 2019

Q3 2020

Q3 2019

452,900

371,679

160,015

143,172

45

462

32

440

17

97

0

-326

287

1,191

102

962

426,723

348,091

151,283

134,113

10,631

7,548

3,784

2,666

6,839

4,701

2,109

1,451

9,057

13,089

2,972

6,019

2,568

1,623

947

519

6,488

11,466

2,025

5,500

527

121

224

52

15

13

1

8

5,976

11,358

1,802

5,457

1,707

3,399

702

1,470

4,269

7,958

1,101

3,987

4,269

7,958

1,101

3,987

0.28

0.55

0.07

0.27

0.27

0.54

0.07

0.27

7

Consolidated balance sheet

ASSETS

In € thousand

30/09/2020

31/12/2019

Non-current assets

45,548

37,136

Intangible assets

4,797

2,549

Property, plant and equipment

6,139

3,045

Right of use

34,391

31,260

Financial assets

220

283

Current assets

163,398

79,431

Inventories

32,064

16,053

Trade receivables

57,048

42,805

Other assets

6,839

4,787

Income tax receivables

191

165

Cash and cash equivalents

67,256

15,622

Balance sheet total

208,945

116,567

LIABILITIES

Equity

Subscribed capital

16,085

14,564

Capital reserves

103,828

51,273

Accumulated Group Result

20,058

15,789

Attributable to shareholders in the parent

139,972

81,627

company

Liabilities

Non-current liabilities

11,659

6,253

Financial Liabilities

6,578

2,577

Other provisions

968

0

Deferred tax liabilities

4,113

3,676

Current liabilities

57,314

28,688

Other provisions

388

501

Trade payables

48,987

12,882

Financial liabilities

1,236

3,664

Income tax liabilities

2,786

7,577

Other liabilities

3,918

4,064

Total liabilities

68,974

34,941

Balance sheet total

208,945

116,567

8

Consolidated cash flow statement

In € thousand

Cash flow from operating activities

Net income for the year

Depreciation and amortization on non-current assets

Decrease/increase in provisions

Other non-cash expenses

Increase in inventories, trade receivables and other assets not attributable to investment or financing activities

Decrease/increase in trade payables and other liabilities not attributable to investment or financing activities

Financial result

Income/expenses from the disposal of assets

Income tax expense

Income tax payments

Net cash inflow/outflow from operating activities

Cash flow from investment activities

Payments made for investments in intangible assets

Payments made for investments in property, plant and equipment

Payments from disposals of tangible fixed assets

Payments from disposals of non- current financial assets

Payments for additions to the consolidated group

Interest received

Net cash outflow from investment activities

Cash flow from financing activities

Proceeds from equity injections

Proceeds from financial liabilities

Outflows from the repayment of financial liabilities

Interest paid

Repayments of the leasing liabilities

Net cash inflow from financing activities

Net change in cash and cash equivalents

Cash and cash equivalents at the beginning of the financial year

Cash and cash equivalents at the end of the financial year

9M 2020

9M 2019

Q3 2020

Q3 2019

4,269

7,958

1,101

3,987

2,568

1,623

947

519

-114

-50

-6

81

584

998

195

356

-30,857

-13,744

-26,053

-1,993

34,835

4,337

29,489

-495

512

108

223

43

-1

-865

0

-865

1,707

3,399

702

1,049

-6,557

253

-6,570

253

6,947

4,018

28

2,935

-1,203

-1,496

-532

-1,381

-1,937

-810

-393

104

15

4,183

4

4,183

62

54

21

54

-1,163

0

0

0

15

13

1

8

-4,210

1,943

-899

2,967

51,991

0

-19

0

19,000

0

0

0

-17,500

0

-17,500

0

-735

-137

-308

-68

-881

-349

-356

-88

51,875

-487

-18,182

-155

54,611

5,474

-19,054

5,747

12,645

11,772

86,310

11,499

67,256

17,246

67,256

17,246

9

Consolidated statement of changes in equity

In € thousand

As at 01/01/2020

Net profit for 9M 2020

Benefits for employees settled with equity

Capital increase

Transaction costs from capital increase

As at 30/09/2020

As at 01/01/2019

Net profit for 9M 2019

Reserve for benefits settled with equity

As at 30/09/2019

In € thousand

As at 01/01/2020

Net profit for 9M 2020

Benefits for employees settled with equity

Capital increase

Transaction costs from capital increase

As at 30/09/2020

As at 01/01/2019

Net profit for 9M 2019

Reserve for benefits settled with equity

As at 30/09/2019

Subscribed capital

Capital reserve

Retained earnings

14,564

51,273

15,789

4,269

584

1,521

53,410

-1,440

16,085

103,828

20,058

14,565

49,904

6,029

7,958

998

14,565

50,902

13,988

Attributable to

Equity

shareholders in the

parent company

81,627

81,627

4,269

4,269

584

584

54,931

54,931

-1,440

-1,440

139,972

139,972

70,499

70,499

7,958

7,958

998

998

79,455

79,455

10

This quarterly statement was published on 12 November 2020.

Contact Medios AG Claudia Nickolaus

Head of Investor & Public Relations Heidestraße 9

10557 Berlin Germany

Phone: +49 30 232 566 800

Fax: +49 30 232 566 801

E-Mail:ir@medios.ag www.medios.ag

Disclaimer

This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.

11

Disclaimer

Medios AG published this content on 12 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 November 2020 11:24:04 UTC


© Publicnow 2020
All news about MEDIOS AG
11:01aMEDIOS AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
01/22MEDIOS AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
01/21MEDIOS AG : Release according to Article 41 of the WpHG [the German Securities T..
EQ
01/21PRESS RELEASE : Medios AG: Successful completion of the Cranach Pharma acquisiti..
DJ
01/21MEDIOS AG : Successful completion of the Cranach Pharma acquisition - Market pos..
EQ
2020PRESS RELEASE : Medios AG: Planned takeover of Cranach Pharma GmbH approved by C..
DJ
2020MEDIOS AG : Planned takeover of Cranach Pharma GmbH approved by Cartel Office
EQ
2020MEDIOS : Warburg Research remains its Buy rating
MD
2020MEDIOS : Berenberg reaffirms its Buy rating
MD
2020MEDIOS : Receives a Buy rating from Kepler Cheuvreux
MD
More news
Financials
Sales 2020 620 M 753 M 753 M
Net income 2020 8,00 M 9,71 M 9,71 M
Net cash 2020 57,8 M 70,1 M 70,1 M
P/E ratio 2020 87,9x
Yield 2020 -
Capitalization 603 M 731 M 732 M
EV / Sales 2020 0,88x
EV / Sales 2021 0,47x
Nbr of Employees 276
Free-Float 89,6%
Chart MEDIOS AG
Duration : Period :
Medios AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDIOS AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 47,00 €
Last Close Price 37,50 €
Spread / Highest target 33,3%
Spread / Average Target 25,3%
Spread / Lowest Target 12,0%
EPS Revisions
Managers and Directors
NameTitle
Matthias A. Gärtner Chief Executive Officer
Yann Samson Chairman-Supervisory Board
Mi Young Miehler Chief Operating Officer
Klaus Buß Member-Supervisory Board
Joachim Messner Vice Chairman-Supervisory Board
Sector and Competitors